The ‘real-life’ impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: A large Israeli retrospective cohort study

References

• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007;25:4779–86.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C Study. J Clin Oncol 2008;26:689–90.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.
   PubMed Web of Science ®Google Scholar
• Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: A systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12:89.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–9.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 2012;17:513–24.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Potosky AL, Leglar JM, Warren J. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–67.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Li L, Sanoff HK, Carpenter W IV, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012;30:608–15.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009;20:1842–7.
   PubMed Web of Science ®Google Scholar
• Kozloff M, Ulcickas Yood M, Berlin J, Flynn PJ, Kabbinavar FF, Puride DM, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic cancer: The BRiTE observational cohort study. Oncologist 2009;14:862–70.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Bekaii-Sabb TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI- bavacizumab: Results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486–95.
   PubMed Web of Science ®Google Scholar
• Renouf DJ, Lim HJ, Speers C, Villa D, Gill S, Blanke CD, et al. Survival for metastatic colorectal cancer in the bevacizumab era: A population-based analysis. Clin Colorectal Cancer 2011;10:97–101.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371:1007–16.
   PubMed Web of Science ®Google Scholar